MDT

96.14

-0.57%↓

A

136.19

-1%↓

VEEV

223.11

-0.69%↓

HQY

91.51

-0.5%↓

PHR.US

16.9

-0.59%↓

MDT

96.14

-0.57%↓

A

136.19

-1%↓

VEEV

223.11

-0.69%↓

HQY

91.51

-0.5%↓

PHR.US

16.9

-0.59%↓

MDT

96.14

-0.57%↓

A

136.19

-1%↓

VEEV

223.11

-0.69%↓

HQY

91.51

-0.5%↓

PHR.US

16.9

-0.59%↓

MDT

96.14

-0.57%↓

A

136.19

-1%↓

VEEV

223.11

-0.69%↓

HQY

91.51

-0.5%↓

PHR.US

16.9

-0.59%↓

MDT

96.14

-0.57%↓

A

136.19

-1%↓

VEEV

223.11

-0.69%↓

HQY

91.51

-0.5%↓

PHR.US

16.9

-0.59%↓

Search

Celldex Therapeutics Inc

Uždarymo kaina

SektoriusSveikatos priežiūra

27.04 2.31

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

25.96

Max

27.56

Pagrindiniai rodikliai

By Trading Economics

Pajamos

-10M

-67M

Pelno marža

-7,753.425

Darbuotojai

186

EBITDA

-9.8M

-73M

Rekomendacijos

By TipRanks

Rekomendacijos

Stiprus pirkimas

12 mėnesių prognozė

+102.5% upside

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

224M

1.7B

Ankstesnė atidarymo kaina

24.73

Ankstesnė uždarymo kaina

27.04

Naujienos nuotaikos

By Acuity

50%

50%

157 / 374 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Weak Bullish Evidence

Celldex Therapeutics Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2025-12-31 22:20; UTC

Pagrindinės rinkos jėgos

Outlook Therapeutics Shares Fall After Another FDA Rejection of Macular Degeneration Drug

2025-12-31 17:31; UTC

Pagrindinės rinkos jėgos

OwlTing Climbs on Launch of $10 Million Stock-Buyback Program

2025-12-31 16:30; UTC

Pagrindinės rinkos jėgos

Trump Media Gains on Plan to Distribute Digital Tokens to Shareholders

2025-12-31 15:19; UTC

Pagrindinės rinkos jėgos

Axsome Shares Climb on FDA Fast‑Track for Alzheimer's Drug, Backing for Narcolepsy Filing

2025-12-31 15:17; UTC

Pagrindinės rinkos jėgos

Nike Shares Rise After CEO Hill Buys $1 Million of Shares

2025-12-31 14:37; UTC

Pagrindinės rinkos jėgos

Corcept Shares Fall as FDA Requires More Evidence for Hypercortisolism Drug Application

2025-12-31 21:50; UTC

Rinkos pokalbiai

Basic Materials Roundup: Market Talk

2025-12-31 21:13; UTC

Įsigijimai, susijungimai, perėmimai

10 People to Watch in Wealth Management in 2026 -- Barrons.com

2025-12-31 20:40; UTC

Rinkos pokalbiai

Dollar Posting Its Worst Year Since 2017 -- Market Talk

2025-12-31 20:22; UTC

Rinkos pokalbiai

Oil Posts Loss in a Year Marked By Plentiful Supply -- Market Talk

2025-12-31 19:50; UTC

Rinkos pokalbiai

U.S. Natural Gas Futures Sink on Weather Outlook -- Market Talk

2025-12-31 19:31; UTC

Rinkos pokalbiai

Precious Metals Cap Off Record Runs -- Market Talk

2025-12-31 18:50; UTC

Rinkos pokalbiai

Global Equities Roundup: Market Talk

2025-12-31 18:50; UTC

Rinkos pokalbiai

Canadian Gold Miners Enjoy a Bumper Year in 2025 -- Market Talk

2025-12-31 17:17; UTC

Rinkos pokalbiai

U.S. Natural Gas Inventories Fall Less Than Expected -- Market Talk

2025-12-31 17:16; UTC

Pagrindinės rinkos jėgos

OwlTing Climbs on Launch of $10M Stock-Buyback Program

2025-12-31 17:15; UTC

Rinkos pokalbiai

Global Commodities Roundup: Market Talk

2025-12-31 17:00; UTC

Įsigijimai, susijungimai, perėmimai

Nvidia Is Getting Creative as Options to Use Its Cash Flood Narrow -- Heard on the Street -- WSJ

2025-12-31 15:57; UTC

Įsigijimai, susijungimai, perėmimai

Vanda Pharmaceuticals Shares Jump 30% on Motion Sickness Drug Approval -- Barrons.com

2025-12-31 15:54; UTC

Rinkos pokalbiai

Layoff Data Supports Dollar at End of Losing Year -- Market Talk

2025-12-31 15:02; UTC

Pagrindinės rinkos jėgos

Nike Shares Rise After CEO Hill Buys $1M of Shares

2025-12-31 14:40; UTC

Įsigijimai, susijungimai, perėmimai

Nike CEO Buys $1 Million of Stock as Insiders Bet on a Turnaround -- Barrons.com

2025-12-31 14:20; UTC

Rinkos pokalbiai

Crude Futures On Track to End the Year With Losses -- Market Talk

2025-12-31 13:46; UTC

Rinkos pokalbiai

U.S. Natural Gas Falls on Milder Weather Outlook -- Market Talk

2025-12-31 13:01; UTC

Uždarbis
Įsigijimai, susijungimai, perėmimai

Charles Schwab Is Back on Offense. Its Stock Is a Buy. -- Barrons.com

2025-12-31 11:10; UTC

Rinkos pokalbiai

Copper Remains in Touching Distance of Record Highs -- Market Talk

2025-12-31 10:46; UTC

Rinkos pokalbiai

Euro on Track For Strong Annual Performance -- Market Talk

2025-12-31 10:25; UTC

Rinkos pokalbiai

European Gas Prices Rise But Remain on Track for Heavy Annual Loss -- Market Talk

2025-12-31 10:23; UTC

Rinkos pokalbiai

Chinese Yuan Rises to 31-Month High Against Dollar as Policymakers -- Market Talk

2025-12-31 09:33; UTC

Rinkos pokalbiai

Dollar Set For Worst Annual Performance Since 2017 -- Market Talk

Akcijų palyginimas

Kainos pokytis

Celldex Therapeutics Inc Prognozė

Kainos tikslas

By TipRanks

102.5% į viršų

12 mėnesių prognozė

Vidutinis 55 USD  102.5%

Aukščiausias 90 USD

Žemiausias 24 USD

Remiantis 10 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Celldex Therapeutics Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

10 ratings

9

Pirkti

0

Laikyti

1

Parduoti

Techninis įvertinimas

By Trading Central

18.91 / 20.63Palaikymas ir pasipriešinimas

Trumpalaikis periodas

Weak Bullish Evidence

Vidutinės trukmės periodas

Bullish Evidence

Ilgalaikis periodas

Bearish Evidence

Rinkos nuotaikos

By Acuity

157 / 374 reitingas Sveikatos priežiūra

Naujienos nuotaikos

Neutral

Svyravimai

Žemiau vidurkio

Naujienų apimtis (RCV)

Vidutinis

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Celldex Therapeutics Inc

Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases. The company's clinical development programs CDX-0159, a Phase II monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity. It has research collaboration and license agreements with Yale University. The company was incorporated in 1983 and is headquartered in Hampton, New Jersey.
help-icon Live chat